microbiology, Vol 141, 1585-1592, Copyright © 1995 by Society for General Microbiology

ARTICLES

Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice

S Abdelhak, H Louzir, J Timm, L Blel, Z Benlasfar, M Lagranderie, M Gheorghiu, K Dellagi and B Gicquel
Unite de Genetique Mycobacterienne (CNRS URA 1300), Institut Pasteur de Paris, France.

We have cloned and expressed the gp63 gene of Leishmania major in BCG to develop a recombinant vaccine against zoonotic cutaneous leishmaniasis. Two different expression systems were investigated. The first system consists of pAN, a Mycobacterium paratuberculosis promoter, which drives expression of ORF2, an open reading frame in IS900. This system allows the production of heterologous polypeptides as hybrids with the ORF2 gene product. The second expression system relies on the production of antigenic fragments as fusion proteins with the N-terminal region of Mycobacterium fortuitum beta-lactamase. Both constructs resulted in the production of Gp63 in BCG. The ability of the two recombinant BCG strains to induce protective immunity against a challenge with L. major amastigotes was evaluated after vaccination of susceptible (BALB/c), and resistant (C57BL/6) mice. Recombinant BCG producing Gp63 as a hybrid protein with the N-terminal region of the beta-lactamase elicited significant protection against a challenge with L. major in BALB/c-immunized mice.

This article has been cited by other articles:

				M. Breton, M. J Tremblay, M. Ouellette, and B. Papadopoulou Live Nonpathogenic Parasitic Vector as a Candidate Vaccine against Visceral Leishmaniasis Infect. Immun., October 1, 2005; 73(10): 6372 - 6382. [Abstract] [Full Text] [PDF]

				P. B. Varaldo, L. C. C. Leite, W. O. Dias, E. N. Miyaji, F. I. G. Torres, V. C. Gebara, G. R. G. Armoa, A. S. Campos, D. C. S. Matos, N. Winter, et al. Recombinant Mycobacterium bovis BCG Expressing the Sm14 Antigen of Schistosoma mansoni Protects Mice from Cercarial Challenge Infect. Immun., June 1, 2004; 72(6): 3336 - 3343. [Abstract] [Full Text] [PDF]

				S. Mendez, K. Tabbara, Y. Belkaid, S. Bertholet, D. Verthelyi, D. Klinman, R. A. Seder, and D. L. Sacks Coinjection with CpG-Containing Immunostimulatory Oligodeoxynucleotides Reduces the Pathogenicity of a Live Vaccine against Cutaneous Leishmaniasis but Maintains Its Potency and Durability Infect. Immun., September 1, 2003; 71(9): 5121 - 5129. [Abstract] [Full Text] [PDF]

				F. Afrin, R. Rajesh, K. Anam, M. Gopinath, S. Pal, and N. Ali Characterization of Leishmania donovani Antigens Encapsulated in Liposomes That Induce Protective Immunity in BALB/c Mice Infect. Immun., December 1, 2002; 70(12): 6697 - 6706. [Abstract] [Full Text] [PDF]

				I. Mederle, I. Bourguin, D. Ensergueix, E. Badell, J. Moniz-Peireira, B. Gicquel, and N. Winter Plasmidic versus Insertional Cloning of Heterologous Genes in Mycobacterium bovis BCG: Impact on In Vivo Antigen Persistence and Immune Responses Infect. Immun., January 1, 2002; 70(1): 303 - 314. [Abstract] [Full Text] [PDF]

				J. A. Triccas, W. J. Britton, and B. Gicquel Isolation of strong expression signals of Mycobacterium tuberculosis Microbiology, May 1, 2001; 147(5): 1253 - 1258. [Abstract] [Full Text]

				E. Handman Leishmaniasis: Current Status of Vaccine Development Clin. Microbiol. Rev., April 1, 2001; 14(2): 229 - 243. [Abstract] [Full Text] [PDF]

				E. N. Miyaji, R. P. Mazzantini, W. O. Dias, A. L. T. O. Nascimento, R. Marcovistz, D. S. Matos, I. Raw, N. Winter, B. Gicquel, R. Rappuoli, et al. Induction of Neutralizing Antibodies against Diphtheria Toxin by Priming with Recombinant Mycobacterium bovis BCG Expressing CRM197, a Mutant Diphtheria Toxin Infect. Immun., February 1, 2001; 69(2): 869 - 874. [Abstract] [Full Text] [PDF]

				M. A. Horwitz, G. Harth, B. J. Dillon, and S. Masle Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model PNAS, November 22, 2000; (2000) 250480397. [Abstract] [Full Text]

				I. P. Nascimento, W. O. Dias, R. P. Mazzantini, E. N. Miyaji, M. Gamberini, W. Quintilio, V. C. Gebara, D. F. Cardoso, P. L. Ho, I. Raw, et al. Recombinant Mycobacterium bovis BCG Expressing Pertussis Toxin Subunit S1 Induces Protection against an Intracerebral Challenge with Live Bordetella pertussis in Mice Infect. Immun., September 1, 2000; 68(9): 4877 - 4883. [Abstract] [Full Text] [PDF]

				N. M. A. El-Sayed and J. E. Donelson African Trypanosomes Have Differentially Expressed Genes Encoding Homologues of the Leishmania GP63 Surface Protease J. Biol. Chem., October 17, 1997; 272(42): 26742 - 26748. [Abstract] [Full Text] [PDF]

				M. A. Horwitz, G. Harth, B. J. Dillon, and S. Maslesa-Galic' Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model PNAS, December 5, 2000; 97(25): 13853 - 13858. [Abstract] [Full Text] [PDF]